JP2017524675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524675A5 JP2017524675A5 JP2016573808A JP2016573808A JP2017524675A5 JP 2017524675 A5 JP2017524675 A5 JP 2017524675A5 JP 2016573808 A JP2016573808 A JP 2016573808A JP 2016573808 A JP2016573808 A JP 2016573808A JP 2017524675 A5 JP2017524675 A5 JP 2017524675A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- fxii
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000000429 Factor XII Human genes 0.000 claims 10
- 108010080865 Factor XII Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 208000014674 injury Diseases 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 230000008736 traumatic injury Effects 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 208000020431 spinal cord injury Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- 102100036774 Afamin Human genes 0.000 claims 1
- 101710149366 Afamin Proteins 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 102100029880 Glycodelin Human genes 0.000 claims 1
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 claims 1
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000051433 human GC Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14172910.3 | 2014-06-18 | ||
| EP14172910 | 2014-06-18 | ||
| PCT/EP2015/063760 WO2015193457A1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524675A JP2017524675A (ja) | 2017-08-31 |
| JP2017524675A5 true JP2017524675A5 (enExample) | 2018-07-19 |
| JP7109160B2 JP7109160B2 (ja) | 2022-07-29 |
Family
ID=50972542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573808A Active JP7109160B2 (ja) | 2014-06-18 | 2015-06-18 | 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170114119A1 (enExample) |
| EP (1) | EP3157548B1 (enExample) |
| JP (1) | JP7109160B2 (enExample) |
| KR (1) | KR102513050B1 (enExample) |
| CN (1) | CN106456778A (enExample) |
| AU (1) | AU2015276089B2 (enExample) |
| BR (1) | BR112016029624A2 (enExample) |
| CA (1) | CA2950988C (enExample) |
| DK (1) | DK3157548T3 (enExample) |
| ES (1) | ES2886859T3 (enExample) |
| PL (1) | PL3157548T3 (enExample) |
| WO (1) | WO2015193457A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456778A (zh) | 2014-06-18 | 2017-02-22 | 德国杰特贝林生物制品有限公司 | 在神经创伤性病患中使用因子xii抑制剂进行治疗 |
| MX2018011765A (es) * | 2016-03-30 | 2019-05-20 | Sinntaxis AB | Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros. |
| AU2017247004B2 (en) * | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
| AU2018382222B2 (en) | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| CN113423465B (zh) * | 2018-11-28 | 2024-12-06 | 俄勒冈健康与科学大学 | 治疗性的因子xii抗体 |
| EP4333901A4 (en) * | 2021-05-03 | 2025-07-09 | Harvard College | FC FUSION PROTEIN-BASED THERAPEUTIC AGENT FOR THE TREATMENT OF PANCREATITIS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| ES2407965T3 (es) * | 2004-12-23 | 2013-06-17 | Csl Behring Gmbh | Prevención de la formación y/o estabilización de trombos |
| EP2109457B1 (en) | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
| WO2011069090A1 (en) | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
| WO2012083024A1 (en) | 2010-12-17 | 2012-06-21 | Anthrogenesis Corporation | Treatment of spinal cord injury and traumatic brain injury using placental stem cells |
| DK2683397T3 (en) | 2011-03-09 | 2017-09-18 | Csl Behring Gmbh | FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP6253578B2 (ja) | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用 |
| AU2012311483B2 (en) | 2011-09-24 | 2016-03-10 | Csl Behring Gmbh | Combination therapy using immunoglobulin and C1-inhibitor |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
| JP2017501968A (ja) | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法 |
| US9587903B2 (en) | 2014-02-24 | 2017-03-07 | Brian E. Sullivan | Pneumatic launcher system and method |
| CN106456778A (zh) | 2014-06-18 | 2017-02-22 | 德国杰特贝林生物制品有限公司 | 在神经创伤性病患中使用因子xii抑制剂进行治疗 |
| AU2017247004B2 (en) | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
-
2015
- 2015-06-18 CN CN201580032338.8A patent/CN106456778A/zh active Pending
- 2015-06-18 KR KR1020177001620A patent/KR102513050B1/ko active Active
- 2015-06-18 CA CA2950988A patent/CA2950988C/en active Active
- 2015-06-18 EP EP15741128.1A patent/EP3157548B1/en active Active
- 2015-06-18 PL PL15741128T patent/PL3157548T3/pl unknown
- 2015-06-18 AU AU2015276089A patent/AU2015276089B2/en active Active
- 2015-06-18 US US15/318,550 patent/US20170114119A1/en not_active Abandoned
- 2015-06-18 ES ES15741128T patent/ES2886859T3/es active Active
- 2015-06-18 DK DK15741128.1T patent/DK3157548T3/da active
- 2015-06-18 WO PCT/EP2015/063760 patent/WO2015193457A1/en not_active Ceased
- 2015-06-18 JP JP2016573808A patent/JP7109160B2/ja active Active
- 2015-06-18 BR BR112016029624A patent/BR112016029624A2/pt not_active Application Discontinuation
-
2019
- 2019-10-29 US US16/666,886 patent/US12065481B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| EP3571224B1 (en) | Improved serum albumin binders | |
| JP2024063213A (ja) | 改良された血清アルブミン結合剤 | |
| EP4442709A2 (en) | Improved serum albumin binders | |
| JP2020511113A (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2016537340A5 (enExample) | ||
| JP2026053563A (ja) | 補体関連疾患のための融合タンパク質構築物 | |
| JP2021533204A5 (enExample) | ||
| TW201402608A (zh) | Ｉｌ－１結合蛋白質 | |
| JP2019513748A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| JP2019503987A (ja) | 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| HK40118030A (en) | Improved serum albumin binders | |
| HK40117444A (en) | Improved serum albumin binders | |
| NZ791361B2 (en) | Engineered anti-il-2 antibodies | |
| HK40017968B (en) | Improved serum albumin binders | |
| HK40017968A (en) | Improved serum albumin binders | |
| HK40018516A (en) | Improved serum albumin binders | |
| HK40018516B (en) | Improved serum albumin binders |